Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 71335-2146

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 71335-2146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Alfuzosin Hydrochloride showing its molecular framework including amine, methoxy, and carbonyl groups, as well as the hydrochloride component.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing Alfuzosin plasma concentration (ng/mL) over time (hours) comparing fed and fasted states. The x-axis represents time in hours from 0 to 24, and the y-axis shows Alfuzosin plasma concentration ranging from 0 to 14 ng/mL. Two lines represent the fed condition (higher concentrations) and fasted condition (lower concentrations), each with error bars.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing mean change from baseline on the IPSS total symptom score over 84 days of treatment. Two groups are compared: placebo (triangle markers) and alfuzosin hydrochloride extended-release tablets (square markers). The graph shows greater symptom score reduction for the alfuzosin group compared to placebo, with statistical significance noted (p < 0.001).*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph depicting mean change from baseline in IPSS total symptom score over 84 days of treatment. The graph compares placebo and Alfuzosin hydrochloride extended-release tablets, showing greater symptom score reduction for Alfuzosin over time with statistical significance indicated at day 84 (p < 0.01).*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line chart depicting the mean change from baseline in IPSS Total Symptom Score over 84 days of treatment comparing placebo (N=150) and Alfuzosin hydrochloride extended-release tablets (N=151). The Y-axis shows mean change values, and the X-axis shows days of treatment (0, 28, 56, 84). The graph indicates a greater symptom score reduction with Alfuzosin over time, with statistical significance noted at day 84 (p < 0.01).*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph comparing mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment between placebo and alfuzosin hydrochloride extended-release tablets. The graph shows a consistent increase for alfuzosin from day 0 to 84, with no significant change for placebo. Statistical significance is noted at p < 0.001.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A line graph titled 'Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2' showing mean change in mL/s on the vertical axis and days of treatment on the horizontal axis (0 to 84 days). It compares placebo (dashed line with triangles) and alfuzosin hydrochloride extended-release tablets (solid line with squares). The alfuzosin group shows greater mean increase in peak urine flow rate over time compared to placebo, with a statistically significant difference at day 84 (p < 0.05).*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A line graph comparing mean change from baseline in peak urine flow rate in mL/s over 84 days of treatment between placebo and Alfuzosin hydrochloride extended-release tablets. The X-axis represents days of treatment; the Y-axis shows mean change in mL/s. Data points and lines show higher mean changes with Alfuzosin compared to placebo, with sample sizes of 151 and 150 respectively. Statistical notation indicates no significant difference (NS) at day 84.*
FDA Label Image

Label (Lbl713352146)

Label (Lbl713352146)
Label for Alfuzosin Hydrochloride ER 10 mg tablet, extended-release oral dosage form. The label indicates the product is packaged by Bryant Ranch Prepack in Burbank, CA. It includes the NDC number 71335-2146-1, lot number, storage instructions (store at 20°-25°C), and a warning to keep out of reach of children. The label also references comparison to Uroxatral 10 mg tablets by Sun Pharmaceutical Industries Ltd.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.